You are viewing: India Drug Discovery Technologies Market analysis

The India Drug Discovery Technologies Market was valued at $576.8 Million in 2025 and projected to reach to $963.9 Million by 2030, representing a compound annual growth rate of CAGR 10.8%. India's drug discovery technologies market is poised for sustained growth, driven by increased pharmaceutical R&D investments and the emergence of innovative biotech startups across major cities.

India Drug Discovery Technologies Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Drug Discovery Technologies Market Trends and Insights

  • India's pharmaceutical sector is increasingly adopting advanced drug discovery technologies, driven by rising R&D investments and a growing number of biotech startups.
  • The market in India benefits from a large pool of skilled scientific talent, cost-effective research capabilities, and government initiatives supporting innovation in the healthcare sector. The expansion of India's drug discovery technologies market reflects the country's strategic positioning as a global hub for pharmaceutical research and development.
  • India's competitive advantage in contract research and manufacturing services (CRAMS) continues to attract international pharmaceutical companies seeking cost-efficient drug discovery solutions.
  • Between 2025 and 2030, India is expected to see increased adoption of artificial intelligence, machine learning, and high-throughput screening technologies in drug discovery processes, further accelerating market growth and establishing India as a key player in the global drug discovery landscape..

Key Market Statistics

  • CAGR (2025-2030) CAGR 10.8%
  • Market Size, 2025 ~USD 576.8 Million
  • Forecast, 2030 ~USD 963.9 Million
  • Country India

India Drug Discovery Technologies Market Overview

Market Valuation Growth :

India's drug discovery technologies market is valued at USD 576.8 million in 2025 and is projected to reach USD 963.9 million by 2030, demonstrating strong market expansion potential with a CAGR of 10.8%.

Rising R&D Investments :

Indian pharmaceutical companies and biotech firms are significantly increasing R&D expenditures, driving adoption of cutting-edge drug discovery platforms and technologies to enhance innovation capabilities.

Biotech Startup Ecosystem :

India's thriving biotech startup landscape is accelerating the adoption of advanced drug discovery technologies, with emerging companies leveraging AI, machine learning, and high-throughput screening solutions.

Competitive Advantage :

India's cost-effective drug discovery services, skilled scientific workforce, and regulatory support position the country as a preferred destination for global pharmaceutical companies outsourcing discovery research.

India Drug Discovery Technologies Market Dynamics

  • The government's supportive policies, coupled with India's reputation as a cost-effective research hub, are attracting both domestic and international pharmaceutical companies to establish discovery centers.
  • The adoption of AI-driven drug discovery platforms and advanced analytical technologies is accelerating, enabling faster time-to-market for new therapeutics.
  • By 2030, India is expected to become a significant player in global drug discovery innovation, with expanding capabilities in personalized medicine and precision therapeutics..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • India's drug discovery technologies market is valued at USD 576.8 million in 2025 and is forecast to reach USD 963.9 million by 2030, growing at a CAGR of 10.8%.
    • India's cost-effective research capabilities and large skilled workforce position the country as a preferred destination for global pharmaceutical companies outsourcing drug discovery activities.
    • Increasing adoption of AI, machine learning, and high-throughput screening technologies in India is driving innovation and accelerating the drug discovery process.
    • Government support and rising private sector R&D investments in India are creating a favorable ecosystem for drug discovery technology adoption and market expansion.

    Drug Discovery Technologies Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES (Technology)
    Forecast Period 2025–2030
    Growth Rate CAGR of 11% from 2025 to 2030
    Largest Segment REAGENTS & CONSUMABLES (Product)
    Market Size Base Year (Billions) ~USD 30.57 (2025)
    Revenue Forecast (Billions) ~USD 51.51 (2030)
    Segments Covered Product, Technology, Type, Process

    India Drug Discovery Technologies Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Product

    • Bioinformatics Tools & Software
    • Instruments
    • Reagents & Consumables

    By Technology

    • Chromatography
    • High-Throughput Screening (Hts) Technologies
    • In-Silico/ AI-Based Drug Discovery Technologies
    • Mass Spectrometry
    • Next-Generation Sequencing
    • Other Technologies
    • Polymerase Chain Reaction
    • X-Ray Crystallography

    By Type

    • Automated Liquid Handling
    • Lab-On-A Chip
    • Label-Free Technology
    • Microplate-Based Hts

    By Process

    • Candidate Validation
    • Hit-To-Lead Identification
    • Lead Optimization
    • Target Identification
    • Target Validation

    INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES93.496.1103.1112.8123.9137.4154.4175.711.2
    CONTRACT RESEARCH ORGANIZATIONS (CROS)219.8228.2247.3273.1302.9339.4385.1442.912.4
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES574.7599.6652.8724.4807908.51035.61196.612.9
    TOTAL887.9923.91003.21110.31233.71385.315751815.212.6

    Target Audience

    • Pharmaceutical Companies : Global and Indian pharma firms need India market data to optimize R&D investments, identify outsourcing opportunities, and benchmark their drug discovery capabilities against market trends.
    • Biotech Startups : Emerging biotech companies require market insights to understand funding landscapes, technology adoption rates, and competitive positioning to secure investments and accelerate growth in India.
    • Contract Research Organizations (CROs) : CROs operating in India need detailed market analysis to expand service offerings, identify client segments, and demonstrate market opportunity to investors and stakeholders.
    • Technology & Software Providers : Drug discovery technology vendors require India-specific market data to tailor solutions, identify adoption rates, and develop targeted go-to-market strategies for the Indian pharmaceutical sector.
    • Investment & Venture Capital Firms : Investors seeking exposure to India's biotech and pharmaceutical innovation need comprehensive market intelligence to identify high-potential startups, assess market growth, and make informed funding decisions.

    Key Companies in the India Drug Discovery Technologies Market

    CompanyHQOwnershipStrongest segments
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    MERCK KGAAGermanyPublic CompanyLife Science (tools, reagents, bioprocessing, CDMO),Healthcare (oncology, neurology, fertility, rare diseases),Electronics (semiconductor and display materials, gases, equipment),
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    REVVITYUnited StatesPublic CompanyDiagnostics instruments and systems,Diagnostics reagents, assays, and kits,Life science reagents and consumables,
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables,
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (instruments, reagents, genomics, and imaging),Diagnostics (clinical instruments, consumables, software, services),
    BRUKERUnited StatesPublic CompanyBSI BioSpin (NMR/EPR and preclinical imaging),BSI CALID (mass spectrometry and diagnostics),BSI Nano (X-ray, AFM, EM analytics, optical microscopy),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics (incl. TB IGRA),Oncology and sexual & reproductive health assays,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Instruments and Systems,Life Science Reagents and Consumables,
    TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR systems, cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, connectivity hardware),Display glass substrates (LCD and OLED),Specialty materials and optics,
    HAMILTON COMPANYUnited StatesPublic Investment FirmPrimary and secondary fund-of-funds,Direct credit and direct investments,Evergreen and customized solutions,
    PACBIOUnited StatesPublic CompanyLong-read instruments (Revio, Sequel, Vega),Long-read consumables and SMRT cells,Short-read Onso platform and consumables,

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a leading United States-based life sciences company founded in 1956, employing 125,000 people globally. Operating as a public company, it provides a comprehensive portfolio of products and services for research, diagnostics, and bioproduction.

    MERCK KGAA

    Merck KGaA is a German multinational science and technology company with roots dating back to 1668, currently employing 59,077 people. As a public company, it operates across pharmaceuticals, life sciences, and performance materials sectors.

    AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company specializes in life sciences, diagnostics, and applied chemical markets with analytical instruments and services.

    REVVITY

    Revvity is a United States public company established in 1937, employing 11,000 people. It provides analytical and diagnostic solutions for life sciences, diagnostics, and applied markets.

    ILLUMINA, INC.

    Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees. The company is a leader in DNA sequencing and genetic analysis technologies for research, diagnostics, and clinical applications.

    DANAHER CORPORATION

    Danaher Corporation is a diversified United States public company founded in 1969, employing 59,000 people worldwide. It operates across multiple segments including life sciences, diagnostics, environmental and applied solutions.

    BRUKER

    Bruker is a United States-based public company founded in 1960 with 11,085 employees. It manufactures scientific instruments for molecular and materials research, including mass spectrometry and NMR systems.

    QIAGEN

    QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. It specializes in sample and assay technologies for molecular diagnostics, applied testing, and life sciences research.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a United States public company established in 1952 with 7,450 employees. It develops and manufactures clinical diagnostics and life science research products.

    TAKARA BIO INC.

    Takara Bio Inc. is a Japanese private company founded in 2002 with 1,779 employees. It develops and manufactures reagents and instruments for life science research and biotechnology applications.

    CORNING INCORPORATED

    Corning Incorporated is a United States public company with a history dating to 1851, employing 67,200 people. It operates across multiple industries including life sciences, with products for research, diagnostics, and bioproduction.

    HAMILTON COMPANY

    Hamilton Company is a United States-based public investment firm founded in 1991 with 785 employees. It provides laboratory automation and liquid handling solutions for life sciences and diagnostics.

    PACBIO

    PacBio is a United States public company founded in 2000 with 485 employees. It develops long-read DNA sequencing systems and services for genomics research and clinical applications.

    Reasons to Buy this Report

    • Market Size & Growth Projections : Access detailed valuation data showing India's market growing from USD 576.8M to USD 963.9M (2030), enabling accurate forecasting and investment planning for the Indian drug discovery sector.
    • Competitive Landscape Analysis : Understand India's positioning as a cost-effective drug discovery hub compared to global markets, identifying opportunities for market entry, partnerships, and competitive differentiation strategies.
    • Technology Adoption Trends : Gain insights into which drug discovery technologies are gaining traction in India, including AI, machine learning, and high-throughput screening, to align product development and marketing strategies.
    • Investment & Funding Opportunities : Identify emerging biotech startups and R&D centers in India seeking advanced drug discovery solutions, enabling targeted business development and partnership opportunities in a high-growth market.
    • Regulatory & Market Entry Insights : Understand India-specific regulatory frameworks, government incentives, and market dynamics essential for successful market entry, expansion, or strategic collaboration in the drug discovery sector.

    Frequently asked questions

    What is the current size of India's drug discovery technologies market?

    India's drug discovery technologies market is valued at USD 576.8 million in 2025 and is expected to grow to USD 963.9 million by 2030.

    What is the projected growth rate for India's drug discovery technologies market?

    India's drug discovery technologies market is projected to grow at a compound annual growth rate (CAGR) of 10.8% from 2025 to 2030.

    Why is India becoming a hub for drug discovery technologies?

    India is becoming a hub for drug discovery technologies due to its cost-effective research capabilities, large pool of skilled scientists, strong pharmaceutical manufacturing base, and government initiatives supporting healthcare innovation.

    What technologies are driving growth in India's drug discovery market?

    Artificial intelligence, machine learning, high-throughput screening, and advanced computational biology tools are key technologies driving growth in India's drug discovery market.

    How much will India's drug discovery technologies market grow by 2030?

    India's drug discovery technologies market is expected to grow by USD 387.1 million from 2025 to 2030, representing a 67.1% increase over the five-year forecast period.

    RESEARCH METHODOLOGY

    The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global drug discovery technologies market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size is estimated through secondary research (top-down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the drug discovery technologies market. The secondary sources used for this study include World Health Organization (WHO), Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Pharmaceutical Research and Manufacturers of America (PhRMA), India Brand Equity Foundation (IBEF), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analysed to arrive at the market size of the global drug discovery technologies market, which was further validated through primary research.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global drug discovery technologies market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biopharmaceutical industries, academic institutes, and others from the supply side, such as C-level and D-level executives, product/ managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug discovery technologies market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Drug Discovery Technologies Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Drug discovery is the process of developing a therapeutically active substance for a defined target molecule. Drug discovery is the early phase in which target identification, target validation, hit-to-lead identification, lead optimization, and candidate validation take place to deliver any suitable molecule or candidate for drug development. Drug discovery technologies are provided by contract research organizations (CROs) to pharmaceutical companies.

    Stakeholders

    • Drug discovery service providers
    • Pharmaceutical and biotechnology companies
    • Academic & Research Institutes
    • Contract Research Organization
    • Market Research and Consulting Firms
    • R&D Centers
    • Researchers and Scientists
    • Regulatory Agencies
    • Venture Capitalists
    • Government Organizations
    • Industry Associations and Professional Societies

    Report Objectives

    • To define, describe, and forecast the drug discovery technologies market by value by process, type, drug type, therapeutic area, end user and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall drug discovery technologies market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Drug Discovery Technologies Market Report

    Full forecast, segment splits, and company analysis for all Drug Discovery Technologies Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status